Metformin and Cancer: Is This the End?

Affiliations

¹ Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: emily.gallagher@mssm.edu.
² Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Population Health Science and Policy, Center for Health Equity and Community-Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York.

Comment

Emily J Gallagher et al. Endocr Pract. 2022 Aug.

. 2022 Aug;28(8):832-834.

doi: 10.1016/j.eprac.2022.06.005. Epub 2022 Jun 18.

¹ Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: emily.gallagher@mssm.edu.
² Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York.
³ Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Population Health Science and Policy, Center for Health Equity and Community-Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York.
⁴ Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, New York.

No abstract available

Keywords: MA.32; breast cancer; insulin resistance; metformin.

Comment on

Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR. Goodwin PJ, et al. JAMA. 2022 May 24;327(20):1963-1973. doi: 10.1001/jama.2022.6147. JAMA. 2022. PMID: 35608580 Free PMC article. Clinical Trial.